Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

CDC panel: Healthcare workers and nursing home residents should be among first to get COVID-19 vaccine

By Brian Buntz | December 1, 2020

A Centers for Disease Control and Prevention (CDC) advisory panel voted 13 to 1 to prioritize COVID-19 vaccines for healthcare workers and residents of long-term facilities after FDA authorizes their use.  

The panel’s recommendations include three-tiers — Phases 1A, 1B and 1C — for early vaccinations. Officials with the federal government’s Operation Warp Speed have said that state governments will choose who gets COVID-19 vaccines first, but CDC guidance will weigh heavily on the decisionmaking. 

Phase 1A will be the first group. 

Potentially next in line for the vaccines will be essential workers, people with high-risk medical conditions and adults 65 or older, who would fall under Phase 1B in a CDC proposed grouping. 

More than 260 million Americans would fall under the broader proposed Phase 1 vaccination scheme, including 87 non-healthcare workers, more than 100 million adults with high-risk medical conditions and 53 million seniors. “The elderly are much more likely to get severe disease and die,” said epidemiologist Megan Murray in a conversation with Elana Gordon, a journalist at The World. By contrast, the rate of COVID-19 infection among healthcare workers has been lower than expected, Murray said.  

Healthcare workers have a significant risk of contracting the novel coronavirus. As of Nov 21., at least 228,503 healthcare workers had been sickened by the virus. Among them were 822 deaths.

The CDC Advisory Committee on Immunization Practices (ACIP) panel has held a series of meetings since the beginning of the pandemic to discuss topics ranging from vaccine prioritization to adverse event monitoring. 

A vaccine could be available in the coming weeks. Both Pfizer (NYSE:PFE) and Moderna (NSDQ:MRNA) have filed for emergency use authorization for their respective SARS-CoV-2 vaccines. 

The vaccine might not be broadly available until April, May or June of next year, according to the epidemiologist Murray.


Filed Under: Drug Discovery, Infectious Disease
Tagged With: CDC, coronavirus, covid-19, COVID-19 vaccine, FDA, U.S. Centers for Disease Control and Prevention (CDC)
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at [email protected].

Related Articles Read More >

Moderna, Merck move toward filing for personalized melanoma therapy as COVID sales lift Q3
Cancer vaccine borrows COVID immune memory to activate T cells against tumors in mice 
AbbVie’s Maviret cured 96% of HCV trial participants. The real world is more complicated.   
FDA greenlights ViiV’s Tivicay PD for HIV-positive newborns in first month of life
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE